Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.

Area of Science:

• Molecular Biology
• Biochemistry
• Computational Chemistry

Background:

• Signal transducers and activators of transcription (STATs) are key in cellular signaling pathways, and their abnormal activation is linked to diseases such as cancer and autoimmune disorders.
• Current STAT-targeting inhibitors, primarily for STAT3, often lack specificity, raising concerns about their therapeutic efficacy and safety.
• The conserved SH2 domain in STATs is critical for their function, mediating interactions with phosphotyrosine motifs, but cross-reactivity among STAT family members complicates inhibitor design.

Purpose of the Study:

• To address the lack of specificity in existing STAT inhibitors by developing a novel computational screening strategy.
• To gain deeper insights into the cross-binding specificities of STAT inhibitors within the human STAT (hSTAT) family.
• To identify specific inhibitors for STAT1 and STAT3 using advanced in silico docking and comparative screening methods.

Main Methods:

• Generation of new 3D structure models for all human STATs (hSTATs).
• Development of a comparative in silico docking strategy to analyze the binding specificities of STAT inhibitors.
• Screening of natural product and large compound libraries using virtual screening and docking validation, incorporating 'STAT-comparative binding affinity value' and 'ligand binding pose variation' as criteria.

Main Results:

• Existing STAT3 inhibitors showed similar binding affinities across multiple STATs when targeting the conserved pTyr-SH2 binding pocket.
• Comparative screening successfully identified potential STAT1- and STAT3-specific inhibitors from natural product and compound libraries.
• A novel STAT inhibitor screening tool was developed, demonstrating the feasibility of identifying highly specific STAT1 and STAT3 inhibitory compounds.

Conclusions:

• The developed computational tool enhances the identification of specific STAT1 and STAT3 inhibitors, overcoming limitations of current non-specific drugs.
• This approach can improve our understanding of STAT functions in various diseases and accelerate the development of more effective and targeted STAT-based therapeutics.
• The findings support the clinical need for STAT inhibitors with high specificity, potency, and favorable pharmacokinetic profiles.